Methods: Openprescribing.net is a publically available resource to simplify analysis of NHS prescribing data published monthly by the Health and Social Care Information Centre. Analysis of all prescribed drugs is available by practice and by clinical commissioning group (CCG). Using this tool, we reviewed prescribing patterns for MTX, SSZ, LEF and HCQ with regard to the average number of prescriptions issued nationally per month between January and June 2011 compared with January-June 2015 and also prescriptions per 1000 population (Rx/1000) from January to June 2015 by the 211 CCGs in NHS England. Results: Analysis of the numbers of prescriptions issued reveals an increase in utilisation for all four drugs: MTX, þ17.5% (140 442/month increasing to 165 025/month); SSZ, þ10.2% (61 467/month to 67 755/ month); LEF, þ25.0% (11 028/month to 13 791/month); HCQ, þ67% (48 356/month to 81 127/month). The number of prescriptions by CCG reveals a typical ski slope graph. As the data are based on primary care prescribing and in some CCGs the responsibility for DMARD prescribing lies wholly within secondary care, the lowest prescribing 10% of CCGs were excluded from the analysis. For all drugs there is considerable variation between the lowest and highest prescribing regions (Table 1) , and although there is less difference between the mode and highest, there remains an up to 2.8-fold difference. Conclusion: Although other disciplines use these medications, local analysis suggests that rheumatic conditions are responsible for >90% of prescriptions. There has been little change in the prescribing patterns for other disciplines, so we feel these data provide a reliable longitudinal surrogate marker of rheumatology activity. The lowest to highest vs mode to highest difference in CCG prescribing suggests the bottom 10% cut-off is probably not enough and there is a greater reliance on secondary care prescribing than anticipated. The increase in the total number of prescriptions suggests that the message of early aggressive therapy is getting through. The marked increase in HCQ suggests that the message of combination therapy is likewise taking hold. However, the increase in LEF prescribing seems to coincide more with the price reduction as it came off patent. With different local policies, the lowest:highest ratio between CCGs is probably not reliable, but the variation between mean to highest suggests that there are still regional differences that need to be reviewed. 
